Download MendeleymRNA-based VP8* nanoparticle vaccines against rotavirus are highly immunogenic in rodents.
Roier, S., Mangala Prasad, V., McNeal, M.M., Lee, K.K., Petsch, B., Rauch, S.(2023) NPJ Vaccines 8: 190-190
- PubMed: 38129390
- DOI: https://doi.org/10.1038/s41541-023-00790-z
- Primary Citation of Related Structures:
8F25 - PubMed Abstract:
Despite the availability of live-attenuated oral vaccines, rotavirus remains a major cause of severe childhood diarrhea worldwide. Due to the growing demand for parenteral rotavirus vaccines, we developed mRNA-based vaccine candidates targeting the viral spike protein VP8*. Our monomeric P2 (universal T cell epitope)-VP8* mRNA design is equivalent to a protein vaccine currently in clinical development, while LS (lumazine synthase)-P2-VP8* was designed to form nanoparticles. Cyro-electron microscopy and western blotting-based data presented here suggest that proteins derived from LS-P2-VP8* mRNA are secreted in vitro and self-assemble into 60-mer nanoparticles displaying VP8*. mRNA encoded VP8* was immunogenic in rodents and introduced both humoral and cellular responses. LS-P2-VP8* induced superior humoral responses to P2-VP8* in guinea pigs, both as monovalent and trivalent vaccines, with encouraging responses detected against the most prevalent P genotypes. Overall, our data provide evidence that trivalent LS-P2-VP8* represents a promising mRNA-based next-generation rotavirus vaccine candidate.
Organizational Affiliation:
CureVac SE, Tübingen, Germany.
